News

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers 

Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQSEATTLE, Oct. 11,…

2 years ago

357 Kerbsyde Last-Mile Delivery Service Celebrates 1st Year Growth, Focusing on 3PL Expansion for E-commerce, Retail Brands, Cosmetics and Meal Kits

The 357 Company The 357 Company’s Kerbsyde last-mile delivery service leverages strong carrier management skills and advanced delivery management and…

2 years ago

Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

Data to be featured in one poster and two oral presentationsWATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences,…

2 years ago

TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors

GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on discovery and development of novel…

2 years ago

Benefytt Technologies Appoints Irene Kwak as Chief Growth Officer

TAMPA, Fla., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Benefytt Technologies, Inc. (“Benefytt” or the “Company”), a health insurance technology company…

2 years ago

Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments

- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -…

2 years ago

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing…

2 years ago

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 monthsFLORHAM PARK, N.J., Oct.…

2 years ago

SmileDirectClub to Report Third Quarter 2022 Results on November 7, 2022

NASHVILLE, Tenn., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the…

2 years ago

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term…

2 years ago